Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Nov 262013
 

The Hygiology Post ®  is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site (https://senesco.com/newsitem.php?id=286; retrieved on 11-17-2013). As a matter of disclosure : The author continues to be a current shareholder in the company.

A recent article on the Senesco Technologies web site (https://senesco.com/newsitem.php?id=286; obtained on 11-17-2013) began the following way:

 “11/12/2013

Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting

Bridgewater, N.J. (November 12th, 2013) Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (OTC QB: SNTI) announced today that it will make two presentations on its gene regulation technology (SNS01-T) for blood-borne cancer care at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 7-10th in New Orleans, Louisiana. The abstracts are available on the ASH website at www.hematology.org.

 

‘We are pleased to be able to present a poster to provide an update on the current results of our Phase 1b/2a trial,’ stated Dr. Leslie J. Browne, President & CEO of Senesco. ‘Additionally we have been given the opportunity for Catherine Taylor, from Senesco CSO John Thompson’s research laboratory at the University of Waterloo, to make an oral presentation of new results with SNS01-T in non-clinical studies.’ 

Abstracts to Be Presented:

 1. ‘Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma’ – Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I; Saturday, December 7, 2013: 5:30 PM-7:30 PM Hall G (Ernest N. Morial Convention Center)

2. ‘SNS01-T Exhibits Significant Anti-Tumoral Activity In Models Of Multiple Myeloma and Non-Hodgkins B Cell Lymphoma and Induces Cell Death In Malignant But Not Normal B Cells’ – Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Drugs; Tuesday, December 10, 2013: 7:30 AM-9:00 AM, 295-296 (Ernest N. Morial Convention Center)”

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.  © 2013                                    The Hygiology Post ®